Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | MC5R | P33032 | 1/20 | 0.68 |
| ▸ | MC3R | P41968 | 1/20 | 0.68 |
| ▸ | MC1R | Q01726 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | MPO | P05164 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | CTSK | P43235 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232881 | 0.85 | MC5R (0.83) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL7970552 | 0.84 | MC5R (0.81) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL379409 | 0.82 | HTR2A (1.00) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL4428860 | 0.82 | HTR2A (0.70) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL106450 | 0.82 | HTR2A (0.70) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL3377341 | 0.82 | HTR2A (0.70) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL29385251 | 0.82 | HTR2A (1.00) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL3377723 | 0.82 | HTR2A (0.70) | HTR2AALDH1A1KDM4EHTR1AHTT | |
| SCHEMBL10089577 | 0.82 | HTR2A (0.70) | HTR2AALDH1A1KDM4EHTR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240189331-A1 | NOVEL TRYPTAMINE ORAL FILM FORMULATION | INTELGENX CORP. (CA) | 2024-06-13 | — | — | US | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | TERRAN BIOSCIENCES INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023092045-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| WO-2007077457-A9 | TREATMENT OF EQUINE LAMINITIS WITH 5-HT1B/ 1D ANTAGONISTS | ROYAL VETERINARY COLLEGE (GB) | 2007-10-18 | — | — | WO | disclosed |
| CN-101049485-A | Mulberry - ginger soft capsule for treating common cold, and preparation method | HE ZUXIN (CN) | 2007-10-10 | — | — | CN | disclosed |
| CN-1898201-A | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION INC (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| US-20030059797-A1 | Animal model of and test for Alzheimer's disease | PALEY ELENA (US) | 2003-03-27 | — | — | US | disclosed |
| US-5798337-A | USED TO PROMOTE GROWTH IN MAMMALS EITHER ALONE OR IN COMBINATION WITH OTHER GROWTH PROMOTING COMPOUNDS | GENENTECH, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5220016-A | Condensing a Grignard reagent of a protected piperidinylmethanol with a protected 2-methoxyoxalylindole; coupling with vidoline;deprotecting and cyclicizing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-15 | — | — | US | disclosed |
| US-4229463-A | ANTICHOLESTEROL AGENTS FOR REDUCING CHOLESTEROL ESTER CONTENT OF ARTERIAL WALLS | SANDOZ, INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4201785-A | ANTICHOLESTEROL AGENTS | SANDOZ INC. (US) | 1980-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | HTR2A 794/4885ALDH1A1 759/4885KDM4E 3806/4885 |
| US-20240189331-A1 | NOVEL TRYPTAMINE ORAL FILM FORMULATION | TPH2, TPH1, HTR2A | HTR2A 3/4885ALDH1A1 3809/4885KDM4E 1171/4885 |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | HTR2A 794/4885ALDH1A1 759/4885KDM4E 3806/4885 |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | FAH, SLC6A3, SLC6A2 | HTR2A 736/4885ALDH1A1 677/4885KDM4E 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.